Leishmaniasis: Complexity at the host-pathogen interface, Nat. Rev. Microbiol, vol.9, pp.604-615, 2011. ,
Cutaneous leishmaniasis: Immune responses in protection and pathogenesis, Nat. Rev. Immunol, vol.16, pp.581-592, 2016. ,
Visceral leishmaniasis: What are the needs for diagnosis, treatment and control?, Nat. Rev. Microbiol, vol.5, pp.873-882, 2007. ,
Worldwide risk factors in leishmaniasis. Asian Pac, J. Trop. Med, vol.9, pp.925-932, 2016. ,
Climate, environmental and socio-economic change: Weighing up the balance in vector-borne disease transmission, Philos. Trans. R. Soc. Lond. B Biol. Sci, vol.370, 2015. ,
Antileishmanial drug discovery: Comprehensive review of the last 10 years, RSC Adv, vol.5, pp.32376-32415, 2015. ,
Infrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasis, PLoS Negl. Trop. Dis, vol.9, 2015. ,
Fungal metabolites and Leishmaniasis: A review, Br. J. Pharm. Res, vol.12, pp.1-12, 2016. ,
Therapeutic switching in leishmania chemotherapy: A distinct approach towards unsatisfied treatment needs, J. Parasitic Dis, vol.35, pp.104-112, 2011. ,
A comprehensive review of patented antileishmanial agents, Pharm. Patent Anal, vol.4, pp.37-56, 2015. ,
Antimony toxicity, Int. J. Environ. Res. Public Health, vol.7, pp.4267-4277, 2010. ,
Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia, Epidemiol. Health, 2016. ,
Leishmaniasis chemotherapy-challenges and opportunities, Clin. Microbiol. Infect, vol.17, pp.1478-1483, 2011. ,
, IJP: Drugs Drug Resist, vol.11, pp.129-138, 2019.
In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series, IJP: Drugs Drug Resist, vol.8, pp.81-86, 2018. ,
Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana, Mol. Biochem. Parasitol, vol.146, pp.198-218, 2006. ,
Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation, Cell. Microbiol, vol.13, pp.978-991, 2011. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01433560
Comparison of the expression profiles of promastigotes and axenic amastigotes in Leishmania donovani using serial analysis of gene expression, Parasitol. Res, vol.103, pp.821-828, 2008. ,
High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: Application to anti-leishmanial drug discovery, PLoS Negl. Trop ,
URL : https://hal.archives-ouvertes.fr/pasteur-01433415
Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening, Sci. Rep, vol.9, 2019. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02017484
New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: An open resource, Sci. Rep, vol.5, 2015. ,
An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages, PLoS Negl. Trop. Dis, vol.6, 1671. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00850256
A screen against Leishmania intracellular amastigotes: Comparison to a promastigote screen and identification of a host cell-specific hit, PLoS Negl. Trop. Dis, 1253. ,
Multiplication of a human parasite (Leishmania donovani) in phagolysosomes of hamster macrophages in vitro, Science, vol.193, pp.678-680, 1976. ,
Hamster macrophage interactions in vitro: Cell entry, intracellular survival, and multiplication of amastigotes, J. Exp. Med, vol.147, pp.515-530, 1978. ,
Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani, Biochem. Pharm, vol.29, pp.2397-2398, 1980. ,
An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani, J. Antimicrob. Chemother, vol.14, pp.463-475, 1984. ,
In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: Practical relevance of stage-specific differences, Antimicrob. Agents Chemother, vol.53, pp.3855-3859, 2009. ,
An in vitro model for screening antileishmanial drugs: The human leukaemia monocyte cell line, THP-1, Acta trop, vol.51, pp.237-245, 1992. ,
Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay, Antimicrob. Agents Chemother, vol.57, pp.2913-2922, 2013. ,
High-content assay for measuring intracellular growth of Leishmania in human macrophages, Assay Drug Dev. Technol, vol.13, pp.389-401, 2015. ,
Screening a natural product-based library against kinetoplastid parasites, vol.22, 1715. ,
Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds, Int. J. Antimicrob. Agents, vol.54, pp.496-501, 2019. ,
Novel chemical starting points for drug discovery in leishmaniasis and Chagas disease, IJP: Drugs Drug Resist, vol.10, pp.58-68, 2019. ,
In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent, J. Antimicrob. Chemother, vol.65, pp.508-511, 2010. ,
Importance of secondary screening with clinical isolates for anti-leishmania drug discovery, Sci. Rep, 2018. ,
In-depth comparison of cell-based methodological approaches to determine drug susceptibility of visceral Leishmania isolates, PLoS Negl. Trop. Dis, vol.13, p.7885, 2019. ,
Leishmania donovani-infected macrophages: Characterization of the parasitophorous vacuole and potential role of this organelle in antigen presentation, J. Cell Sci, vol.107, pp.2137-2150, 1994. ,
Generation of Leishmania donovani axenic amastigotes: Their growth and biological characteristics, Int. J. Parasitol, vol.34, pp.205-217, 2004. ,
Leishmania spp: Temperature sensitivity of promastigotes in vitro as a model for tropism in vivo, Exp. Parasitol, vol.84, pp.400-409, 1996. ,
Biogenesis of Leishmania-harbouring parasitophorous vacuoles following phagocytosis of the metacyclic promastigote or amastigote stages of the parasites, J. Cell Sci, vol.115, pp.2303-2316, 2002. ,
Leishmania donovani resides in modified early endosomes by upregulating Rab5a expression via the downregulation of miR-494, PLoS Pathog, vol.13, 2017. ,
Snapshot Profiling of the Antileishmanial potency of lead compounds and drug candidates against intracellular Leishmania donovani amastigotes, with a focus on human-serived host cells, Antimicrob. Agents Chemother, vol.61, pp.1228-1244, 2017. ,
Chemotherapeutics of visceral leishmaniasis: Present and future developments, Parasitology, vol.145, pp.481-489, 2018. ,
Leishmania amazonensis: Cultivation and characterization of axenic amastigote-like organisms, Exp. Parasitol, vol.83, pp.94-105, 1996. ,
A microplate assay for Leishmania amazonensis promastigotes expressing multimeric green fluorescent protein, Parasitol. Res, vol.89, pp.266-271, 2003. ,
Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents, Antimicrob. Agents Chemother, vol.41, pp.972-976, 1997. ,
,
Development of luciferase expressing Leishmania donovani axenic amastigotes as primary model for in vitro screening of antileishmanial compounds, Curr. Microbiol, vol.65, pp.696-700, 2012. ,
Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice, Cell. Microbiol, vol.7, pp.383-392, 2005. ,
Use of a fluorescent stain for evaluating in vitro infection with Leishmania panamensis, Exp. Parasitol, vol.129, pp.31-35, 2011. ,
A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts, Antimicrob. Agents Chemother, vol.57, pp.3003-3011, 2013. ,
A Replicative in vitro assay for drug discovery against Leishmania donovani, Antimicrob. Agents Chemother, vol.60, pp.3524-3532, 2016. ,
Receptor-mediated phagocytosis of Leishmania: Implications for intracellular survival, Trends Parasitol, vol.28, pp.335-344, 2012. ,
Cell biology and immunology of Leishmania, Immunol. Rev, vol.240, pp.286-296, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00726034
Bone marrow-derived macrophages (BMM): Isolation and applications, Cold Spring Harb. Protoc, vol.3, pp.1-6, 2008. ,
THP-1 cell line: An in vitro cell model for immune modulation approach, Int. Immunopharm, vol.23, pp.37-45, 2014. ,
The human leukemia cell line, THP-1: A multifacetted model for the study of monocyte-macrophage differentiation, Experientia, vol.47, pp.22-31, 1991. ,
Immunological characteristics of experimental murine infection with Leishmania (Leishmania) amazonensis. Veter. Parasitol, vol.158, pp.239-255, 2008. ,
In vitro 'time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum, J. Antimicrob. Chemother, vol.72, pp.428-430, 2017. ,
Haplotype selection as an adaptive mechanism in the protozoan pathogen Leishmania donovani, Nat. Ecol. Evol, vol.1, pp.1961-1969, 2017. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02107201
A method for generation of bone marrow-derived macrophages from cryopreserved mouse bone marrow cells, PLoS ONE, vol.5, 2010. ,